Comprehensive Analysis of Cetuximab Critical Quality Attributes: Impact of Handling on Antigen-Antibody Binding
Thus, we suggest that Erbitux<sup>®</sup> (5 mg/mL) should be shielded from these environmental conditions, as they compromise both the safety and efficacy of the drug product.
Authors
- Anabel Torrente-López (ORCID: https://orcid.org/0000-0002-2507-6760)
- J Cabeza Barrera (ORCID: https://orcid.org/0000-0002-2161-930X)
- Antonio Salmerón‐García
- Natalia Navas (ORCID: https://orcid.org/0000-0002-2536-1430)
- Jesús Hermosilla (ORCID: https://orcid.org/0000-0002-2390-2360)
- Amparo Hernández
- Alicia Torres-García (ORCID: https://orcid.org/0009-0005-6132-6228)
Institutions
- Universidad de Granada (ES)
- Instituto de Investigación Biosanitaria de Granada (ES)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-09-19
- DOI
- https://doi.org/10.3390/pharmaceutics16091222
- Citations
- 3
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Consejería de Transformación Económica, Industria, Conocimiento y Universidades
- Ministerio de Economía y Competitividad
- Universidad de Granada
- Junta de Andalucía
- Instituto de Salud Carlos III
- European Regional Development Fund